Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 9698806 | HLA-DR2 (BROAD ANTIGEN) | alports syndrome | NA | NA | NA | unclassified | |
| association of alport's syndrome with hla-dr2 antigen in a group of unrelated patients. | |||||||
| 9698806 | HLA (HLA) | alports syndrome | NA | NA | NA | negation | |
| a few family studies have evaluated hla antigens in alport's syndrome; however, there are no large population studies. | |||||||
| 9698806 | HLA (HLA) | alports syndrome | NA | NA | NA | unclassified | |
| although few immunological abnormalities have been shown in alport's syndrome, in this report we emphasize the association of hla molecules and alport's syndrome. | |||||||
| 7304161 | HLA (HLA) | adrenogenital syndrome | NA | NA | NA | unclassified | |
| hla haplotypes in children with adrenogenital syndrome and their parents. | |||||||
| 7304161 | HLA-A (HLA-A) | adrenogenital syndrome | NA | NA | NA | only_studied | |
| hla-a and b antigen typing was carried out by the standard nih lymphocytotoxicity test in children with adrenogenital syndrome (ags) from 11 families, further in 3 healthy siblings and 20 obligatory gene carrier parents. | |||||||
| 7347488 | HLA (HLA) | alcaptonuria | NA | NA | NA | only_studied | |
| intestinal brush border membrane hydrolases and hla lymphocyte antigens have been examined in three siblings with sucrose intolerance and alcaptonuria, and their consanguineous parents. | |||||||
| 12917799 | HLA-DQB1 (HLA-DQB1) | diabetes type 1 | Caucasian | NA | NA | unclassified | |
| association between diabetes type 1 and dqb1 alleles in a case-control study conducted in montevideo, uruguay. | |||||||
| 20699420 | HLA-DRB1*04 | diabetes type 1 | NA | insulin | NA | unclassified | |
| the medalist cohort, with a mean +- sd disease duration and age of 56.2 +- 5.8 and 67.2 +- 7.5 years, respectively, has a clinical phenotype similar to type 1 diabetes (type 1 diabetes): mean +- sd onset at 11.0 +- 6.4 years, bmi at 26.0 +- 5.1 kg/m(2), insulin dose of 0.46 +- 0.2 u/kg, ~94% positive for dr3 and/or dr4, and 29.5% positive for either ia2 or glutamic acid decarboxylase (gad) autoantibodies. | |||||||
| 20699420 | HLA-DR3 (BROAD ANTIGEN) | diabetes type 1 | NA | insulin | NA | unclassified | |
| the medalist cohort, with a mean +- sd disease duration and age of 56.2 +- 5.8 and 67.2 +- 7.5 years, respectively, has a clinical phenotype similar to type 1 diabetes (type 1 diabetes): mean +- sd onset at 11.0 +- 6.4 years, bmi at 26.0 +- 5.1 kg/m(2), insulin dose of 0.46 +- 0.2 u/kg, ~94% positive for dr3 and/or dr4, and 29.5% positive for either ia2 or glutamic acid decarboxylase (gad) autoantibodies. | |||||||
| 32221414 | NA (NA) | diabetes type 1 | African | NA | NA | unclassified | |
| current study identified high prevalence of the diabetes type 1 (t1d) predisposing hla dr-dq haplotypes in somalia. | |||||||
Copyright 2024